Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | EXEC. VP AND CLO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,272 |
Ending reported balance
After 2026-10-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04 | Direct | 2,267 |
Reported balance
After 2026-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 548 | $45.00 | $24,660.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 14 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 548 | $18.01 | $9,869.48 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 13 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,405 | $18.01 Strike: $18.01 | $25,304.05 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 26 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,445 Underlying: Common Stock · 1,405 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F10 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,800 | $18.01 Strike: $18.01 | $32,418.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 25 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,850 Underlying: Common Stock · 1,800 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F10 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $18.01 Strike: $18.01 | $27,015.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 24 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,650 Underlying: Common Stock · 1,500 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F10 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,100 | $18.01 Strike: $18.01 | $19,811.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 23 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,150 Underlying: Common Stock · 1,100 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F10 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $11.23 Strike: $11.23 | $11,230.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 22 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,563 Underlying: Common Stock · 1,000 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,000 | $11.23 Strike: $11.23 | $11,230.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 21 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,563 Underlying: Common Stock · 1,000 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,405 | $45.23 | $63,545.34 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.08 to $45.42 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,405 | $18.01 | $25,304.05 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,800 | $45.20 | $81,360.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.01 to $45.42 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,800 | $18.01 | $32,418.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,500 | $45.22 | $67,831.50 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.08 to $45.42 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,500 | $18.01 | $27,015.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,100 | $45.21 | $49,732.10 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.01 to $45.42 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,100 | $18.01 | $19,811.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,000 | $45.25 | $45,254.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.11 to $45.44 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,000 | $11.23 | $11,230.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,000 | $45.25 | $45,245.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.11 to $45.40 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,000 | $11.23 | $11,230.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 23:23 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 778 | $56.96 | $44,311.77 |
DisclosureSEC source: 0001179110-21-001100 · edgar.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 29, 2020 grant of 10,200 RSUs. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 59,500 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001179110-21-000473 · edgar.xml · derivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,500 Underlying: Common Stock · 59,500 shares Expires 2031-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000473 · edgar.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,152 F1 · shares: Restricted stock units granted on January 6, 2021 that vest in four equal installments over four years, commencing on January 6, 2022. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 22:05 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 772 | $62.37 | $48,149.64 |
DisclosureSEC source: 0001179110-21-000416 · edgar.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,952 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,250 shares of restricted stock from a January 3, 2017 grant of 9,000 shares of restricted stock. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 17,500 | $18.01 Strike: $18.01 | $315,175.00 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · derivative · entry 22 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 17,500 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F13 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 13,125 | $11.23 Strike: $11.23 | $147,393.75 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · derivative · entry 21 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,563 Underlying: Common Stock · 13,125 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F12 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $55.73 | $5,573.00 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 20 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,724 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,675 | $55.24 | $203,010.68 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 19 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,824 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.73 to $55.66 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 600 | $54.20 | $32,517.00 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 18 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,499 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.73 to $54.67 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 400 | $55.74 | $22,295.20 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 17 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,099 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F11 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.73 to $55.74 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,350 | $55.23 | $405,955.20 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 16 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,499 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.73 to $55.68 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,000 | $54.20 | $54,202.00 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 15 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,849 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.73 to $54.63 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,775 | $55.26 | $208,591.40 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 14 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,849 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.73 to $55.68 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 600 | $54.20 | $32,517.00 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 13 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,624 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.73 to $54.67 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 17,500 | $18.01 | $315,175.00 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 200 | $55.73 | $11,146.00 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,724 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,301 | $55.23 | $237,535.63 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,924 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.73 to $55.66 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 626 | $54.18 | $33,916.05 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,225 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.73 to $54.63 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,881 | $55.24 | $159,143.56 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,851 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.73 to $55.62 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 400 | $54.15 | $21,659.20 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,732 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.73 to $54.57 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $55.73 | $5,573.00 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,132 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,824 | $55.22 | $155,952.58 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,232 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.73 to $55.66 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 357 | $54.11 | $19,316.91 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,056 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.73 to $54.44 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 962 | $55.31 | $53,205.33 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,413 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.12 to $55.62 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 474 | $54.70 | $25,926.85 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,375 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.12 to $55.05 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 13,125 | $11.23 | $147,393.75 |
DisclosureSEC source: 0001070081-20-000118 · wf-form4_159432531261563.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 4, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:44 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 59,500 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000053 · wf-form4_158050704413579.xml · derivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,500 Underlying: Common Stock · 59,500 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:44 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000053 · wf-form4_158050704413579.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,724 F1 · shares: Restricted stock units granted on January 29, 2020 that vest in four equal installments over four years, commencing on January 29, 2021. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 4,375 | $18.01 Strike: $18.01 | $78,793.75 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · derivative · entry 16 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 4,375 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F9 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 4,375 | $18.01 Strike: $18.01 | $78,793.75 |
DisclosureSEC source: 0001070081-19-000044 · wf-form4_156270565447443.xml · derivative · entry 15 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,125 Underlying: Common Stock · 4,375 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 7, 2018. F9 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.